EuropaBio, Brussels Videos

🟣 To support the uptake of #genetictesting, EuropaBio proposes a set of 12 policy #principles and associated #recommendations, including 3 propositions related to #ethics and #society. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3Po2JS8

🟣 Increased access to genetic testing is a significant opportunity for #patients and #healthcare systems in #Europe by supporting the deployment of targeted therapeutic strategies. 🟣 But investments in #infrastructure are essential to make testing more widely available to support the broader needs of the population. 🟣 To support the uptake of #genetictesting, EuropaBio proposes a set of 12 policy #principles and associated #recommendations, including 3 propositions concerning #infrastructure and #workforce. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3Po2JS8

🟣 #GeneticTests and (non-genetic) tests for genetic risk factors are medical tests used to identify #mutations in genes that correlate to a #patient’s risk of developing a certain #condition. 🟣 Increased access to genetic testing is a significant opportunity for #patients and #healthcare systems in #Europe by supporting the deployment of targeted therapeutic strategies. 🟣 To support the uptake of #genetictesting, EuropaBio proposes a set of 12 policy #principles and associated #recommendations, including 3 propositions concerning #funding and #access. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3Po2JS8

🟣 Advances in science and technology have greatly improved our understanding of the genetic basis of #disease, which have made it possible to redefine many diseases at higher resolution and target them with more precise #treatments such as cell and #genetherapies. 🟣 Increased access to genetic testing is a significant opportunity for #patients and #healthcare systems in #Europe by supporting the deployment of targeted therapeutic strategies. 🟣 To support the uptake of #genetictesting, EuropaBio proposes a set of 12 policy #principles and associated #recommendations. Here are the first 3, about #regulatory pathways. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3Po2JS8

🟣 #ATMP development advances alone do not deliver products to patients. The development pathway requires diverse skills to enable #SMEs to succeed in delivering treatment solutions. 🟣 One of the most significant bottlenecks for SME #growth and technology maturation is access to professional #skills. This experience gap can only be addressed in the short term by greater public and private #collaboration with practices and information sharing 🟣 Read our recommendations in the #SMEBioForum2022 Report: 👉 https://bit.ly/3F4RitS, and register to our #SMEBioForum Webinar, next week: 👉 https://bit.ly/3haNyiq. 🟣 #INNOVATION #INVESTMENT #EXCELLENCE

🟣 For European #SMEs’ growth and survival, it is fundamental to achieve more regulatory #harmonization across Europe to ensure that #therapies find their market with appropriate pricing and reimbursement decisions and that #medicines are available to #patients. 🟣 Read our recommendations in the #SMEBioForum2022 Report: 👉 https://bit.ly/3F4RitS, and register to our #SMEBioForum Webinar, next week: 👉 https://bit.ly/3haNyiq. 🟣 #INNOVATION #INVESTMENT #EXCELLENCE

🟣 The #ATMP development field is recent and fast-evolving. While technology progresses rapidly, national regulators must learn and adapt quickly to support the development and approval of new cell and #genetherapies. 🟣 The European Medicines Agency (EMA) and the EU regulatory network have to deliver a streamlined, flexible and coherent regulatory system, with good coordination between the #EMA and the Member States, optimising support for new advances in #health innovation and accelerating #patientaccess. 🟣 Read our recommendations in the #SMEBioForum2022 Report: 👉 https://bit.ly/3F4RitS, and register to our #SMEBioForum Webinar, next week: 👉 https://bit.ly/3haNyiq. 🟣 #INNOVATION #INVESTMENT #EXCELLENCE

🟣 Last May, the European Commission published the first evaluation of the #CBHC Directive, more than ten years after its adoption. 🟣 The evaluation highlighted the many issues surrounding the Directive as well as the many #barriers that #patients seeking #healthcare across borders face. Read our #recommendations to improve cross-border healthcare in Europe. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3VfavQp

🟣 Cross-border healthcare for #ATMPs in #Europe requires significant planning from #patients and their carers to deal with complex administrative procedures which can vary from one country to the next. 🟣 Better #access to ATMPs in Europe is dependent on a well-functioning cross-border #healthcare framework. Read our recommendations. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE #CBHC 📌 https://bit.ly/3VfavQp

🟣 For patients whose treatment involves #ATMPs, cross-border #healthcare is often the only way to access these transformative #therapies. 🟣 #EuropaBio considers that the evaluation of the #CBHC Directive is a first step in a larger review process of the cross-border healthcare framework to improve #patient access. Read our position. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3VfavQp

🟣 #EuropaBio considers the proposal of a Regulation on #SoHO to be an opportunity for convergence of requirements across Member States and ensure that regulatory standards protecting #patient safety and public #health keep pace with technical and scientific #advances. 🟣 Read our recommendations to ensure the #SoHORegulation can support #ATMP developers in Europe. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3NVB0HW

🟣 As the European Association of innovative #biopharmaceutical and #biotechnology companies representing developers of cell-based and plasma-derived medicines, #EuropaBio is committed to supporting patient access to essential and innovative #therapies and to becoming a global leader in #ATMP innovation. 🟣 This is why we consider the adoption of the proposal for a Regulation on #SoHO revising the EU’s Blood, Tissues, and Cells (#BTC) legislation as an opportunity to ensure regulatory standards protecting patient safety and public #health keep pace with technical and scientific advances. 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3DRV1dO

🟣 The #EuropeanHealthDataSpace marks a global first in providing federated access to important #healthdata. Placing a central focus on citizens’ control over their data, the #EHDS seeks to implement a framework through which data access for primary and secondary use is both clarified and simplified. 🟣 Here are our core #priorities, reflecting on the EHDS legislative proposal, for the use of #healthcare data in the development of novel #biotechnology derived medicines: 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌https://bit.ly/3OcyP2x 📌https://bit.ly/3X9wdqg

🟣 The revision of the #OMP Regulation is the perfect opportunity to establish a regulatory system fit for the 21st Century. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3U13DFy

🟣 The revision of the #OMP Regulation should continue to guarantee the predictability of #incentives to accelerate innovation for #rarediseases. 👇 🟣 #INNOVATION #INVESTMENT #EXCELLENCE 📌 https://bit.ly/3U13DFy